Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Applied Biologics

PharmaDeviceNews Applied Biologics

Representative image of diabetic foot ulcer treatment as Applied Biologics begins its Phase 3 BIOxHEAL trial to evaluate chronic wound healing.

Pharma & Biotech

Applied Biologics treats first patient in pivotal BIOxHEAL diabetic foot ulcer trial

by Soujanya Ravi
October 13, 2026
0 Comments

Applied Biologics begins Phase 3 testing of BIOxHEAL for diabetic foot ulcers. Explore its wound-healing potential and trial milestones.

Read More

Latest news and features

Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?
Gilead is betting nearly $1.9bn on masked cancer drugs. What makes Vir’s technology different?
The FDA rejected tab-cel twice. Can Atara’s third review finally deliver approval?
Sarepta’s RNA therapy reaches the nucleus in myotonic dystrophy models. Can it restore muscle function?
Cyted Health’s EndoSign detects Barrett’s esophagus with 90% sensitivity in US study
JCR’s enzyme therapy reaches Kuwait. Can crossing the blood-brain barrier change Hunter syndrome care?
Can Estrella’s EB103 challenge established CAR-T therapies in B-cell lymphoma?
FDA expands ANKTIVA approval to papillary-only bladder cancer after BCG failure
Aptar’s nasal vaccine device is now CE marked. Could it help bring more needle-free vaccines to market?
Altay Therapeutics closes $37m Series A for FSHD treatment DX5057
Celltrion’s injectable infliximab has taken over 32% share in major European markets. What’s driving adoption?
Takeda’s new narcolepsy drug cuts cataplexy by up to 89%. Can ORZEYFUL transform treatment?

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Pulsed field ablation is emerging as a nonthermal alternative to radiofrequency and cryoballoon ablation, using targeted electrical pulses to isolate pulmonary veins while potentially reducing collateral tissue injury in atrial fibrillation treatment. Representative image.

Pharma & Biotech

Novartis pelacarsen fails 8,323-patient Phase 3 Lp(a)HORIZON cardiovascular trial

September 6, 2026

Latest business and industry news

Universal Music loses Republic and Def Jam chiefs as €250m cost reset reaches labels
Proofpoint to acquire Varonis for $6.3bn as Thoma Bravo targets AI security market
BlackRock’s $15.5tn asset milestone reveals why private markets and ETFs are reshaping its growth
Equinor targets rapid Grimsnes oil development after new North Sea discovery
Mondi shares plunge as €196m quarterly EBITDA masks fresh packaging margin pressure

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.